Figure 1
(A) The time to next treatment (TTNT) of the multiple myeloma (MM) patients treated with elotuzumab. The median TTNT (months) and 95% CI are shown. (B) The TTNT of the MM patients treated with elotuzumab classified according to the κ/λ ratio: 0.1 to 10 (black) and less than 0.1 or 10 or more (red). The median TTNT (months) and 95% CI are shown. (C) The TTNT of the MM patients treated with elotuzumab according to the β2 microglobulin (B2MG); less than 5.5 mg/L (black) and 5.5 mg/L or more (red). The median TTNT (months) and 95% CI are shown. (D) The TTNT of the MM patients treated with elotuzumab classified according to the white blood cell (WBC) counts: less than 3500/μL (black) and 3500/μL or more (red). The median TTNT (months) and 95% CI are shown. (E) The TTNT of the MM patients treated with elotuzumab classified according to the lymphocyte counts: less than 1400/μL (black) and 1400/μL or more (red). The median TTNT (months) and 95% CI are shown. The number of patients at risk in each group is shown in the lower panel of each figure. CI: confidence interval.
